These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25792221)

  • 1. Pegvisomant Treatment in Acromegaly.
    Neggers SJ; Muhammad A; van der Lely AJ
    Neuroendocrinology; 2016; 103(1):59-65. PubMed ID: 25792221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment with somatostatin analogues and pegvisomant in acromegaly.
    Neggers SJ; van der Lely AJ
    Growth Horm IGF Res; 2011 Jun; 21(3):129-33. PubMed ID: 21498099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
    Franck SE; Muhammad A; van der Lely AJ; Neggers SJ
    Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs.
    Colao A; Pivonello R; Cappabianca P; Auriemma RS; De Martino MC; Ciccarelli A; de Divitiis E; Lombardi G
    J Endocrinol Invest; 2003; 26(10 Suppl):53-6. PubMed ID: 15497660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
    Zgliczyński W; Zdunowski P
    Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2009 Jun; 19(3):245-51. PubMed ID: 19109045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
    De Marinis L; Bianchi A; Fusco A; Cimino V; Mormando M; Tilaro L; Mazziotti G; Pontecorvi A; Giustina A
    Pituitary; 2007; 10(3):227-32. PubMed ID: 17484056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study.
    Muhammad A; Coopmans EC; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; van der Lely AJ; Neggers SJCMM
    Eur J Endocrinol; 2018 Oct; 179(5):269-277. PubMed ID: 30076159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
    Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone receptor antagonists.
    van der Lely AJ; Kopchick JJ
    Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
    Neggers SJ; de Herder WW; Janssen JA; Feelders RA; van der Lely AJ
    Eur J Endocrinol; 2009 Apr; 160(4):529-33. PubMed ID: 19141604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegvisomant: new preparation. A last resort in acromegaly.
    Prescrire Int; 2005 Feb; 14(75):10-3. PubMed ID: 15751152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
    Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
    Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin analog and pegvisomant combination therapy for acromegaly.
    Neggers SJ; van der Lely AJ
    Nat Rev Endocrinol; 2009 Oct; 5(10):546-52. PubMed ID: 19763127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of medical therapy in the management of acromegaly.
    Vance ML; Laws ER
    Neurosurgery; 2005 May; 56(5):877-85; discussion 877-85. PubMed ID: 15854234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.